MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Neurology
; 66(9): 1435-8, 2006 May 09.
Article
em En
| MEDLINE
| ID: mdl-16682682
ABSTRACT
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival 41 +/- 7%) was obtained.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfoma não Hodgkin
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Irradiação Craniana
/
Neoplasias do Sistema Nervoso Central
/
Radioterapia Adjuvante
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
Idioma:
En
Revista:
Neurology
Ano de publicação:
2006
Tipo de documento:
Article